本文主要综述近年来国内外阿尔兹海默病(Alzheimer’s disease，AD)相关治疗常见药物，候选药物开发方面的潜在陷阱，有较全面地了解现有AD的治疗药物，为发现新的治疗靶点、研发相关新药提供思路。

[1]赵师德,鲜利群,陈峰.多奈哌齐治疗阿尔茨海默病的临床疗效及其对β淀粉样蛋白、炎性因子的影响研究[J].实用心脑肺血管病杂
志,2018(1)
[2]VANELDIKLJ,COLEPE,etal.The roles of inflammation and immune mechanisms in Alzheimer’s disease[J]Alzheimers Dement
( NY) ,2016,2( 2):99 -109. [3]Zhu, CC, Fu, SY, Chen, YX, et al. Advances in Drug Therapy for Alzheimer's Disease. CURR MED SCI. 2020; 40 CURR MED SCI. [4]EITZ C,MAYEUX.Alzheimer disease:epidemiology,risk factors and biomarkers [J].Biochem Pharmacol,2014,88( 4):640 -651. [5]徐岚,洪震.阿尔茨海默病的药物治疗进展[J].医药导报,2009,28(9):1182-1184. [6]杨南竹,贠相华,周玉颖,等多奈哌齐治疗阿尔茨海默病的系统评价[J].中华老年心脑血管病杂志,2015,17(1):61-66. [7]王翠.银杏内酯 A 防治阿尔茨海默病作用及机制研究[D].合肥:安徽大学,2012. [8]章瑜,谢健.美金刚对阿尔茨海默病患者精神行为症状和睡眠结构的影响[J].浙江医学,2018,40(11):1175-1178. [9]HORTJ，OBRIENJT，GAINOTTIG，etal.EFNS guidelines for the diagnosis and management of Alzheimer’s disease[J].EurJ.Neurol，
2010，17(10):1236-1248. [10]邓青芳,马风伟.阿尔兹海默病的发病机制及药物治疗研究进展[J].贵州师范大学学报（自然科学版）,2020,38(1):104-111. [11]李琳,王晓良,彭英.抗阿尔茨海默病天然产物及其药理学研究进展[J]中国药理学通报,2016,32(2):149-55．
[12]罗科.姜黄素对 AD 大鼠学习记忆及海马 rage-erk12 信号通路的影响[D].温州:温州医学院,2012. [13]DEYA,MUKHEJEEA.Natural products against Alzheimer’s disease: Pharmaco-therapeutics and biotechnological interventions [J]. Biotechnol Adv，2016，35(2):178 -216. [14]王翠.银杏内酯 A 防治阿尔茨海默病作用及机制研究[D].安徽大学,2012. [15]TSOI K K, CHAN J Y, LEUNG N W, et al. Combination therapy showed limited superiority over monotherapy for Alzheimer disease:A Meta-analysis of 14 randomized trials[J].J Am Med Dir Assoc，2016，17(9):1061-1062. [16] SAINT-LAURENTTC,ZERSTILLMAN I, CHEN , et al.Cost-utility analysis of memantine extended release added to cholinesterase
inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer’s type in
the US[J]J Med Econ, 2015, 18( 11):930-943. [17]Riverol, M, Slachevsky, A, López, OL. Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer's Disease: A Literature Review Evidence. Eur Neurol J. 2011; 3 Eur Neurol J. PMID: 25302109
[18]Garay, RP, Grossberg, GT. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type. EXPERT OPIN INV DRUG. 2017; 26 EXPERT OPIN INV DRUG. [19]Canter,Penney J,Tsai L H.The road to restoring neural circuits for thetreatment of Alzheimer’s disease[J]Nature,2016,539(7628):187-96. [20]TAKAHASHI R H, NAGAO T, GOURASGK．Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer’s disease[J].Pathology international,2017,67( 4):185-193.